Retatrutide (LY3437943) Clinical Trials

Size	Price	Qty
1mg	USD 197
5mg	USD 347

Clinical Trials

Retatrutide has been evaluated in multiple clinical trials across Phase 1, Phase 2, and Phase 3 development stages. Prominently sponsored by Eli Lilly and Company alongside Hudson Biotech, these investigations target primary conditions including obesity, overweight, type 2 diabetes mellitus, and metabolic dysfunction-associated steatotic liver disease, while also evaluating comorbidities such as chronic kidney disease and chronic low back pain. Active, recruiting, and completed studies—including NCT07232719, NCT06662383, and NCT05936151—assess the comparative efficacy, safety, and glycemic response of once-weekly administration. Together, these clinical efforts demonstrate a broad evaluation of retatrutide across varied metabolic disorders and healthy participant cohorts.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07165028	RECRUITING	Metabolic Dysfunction-Associated Steatotic Liver Disease	Eli Lilly and Company	2025-10-15	PHASE3
NCT06383390	ACTIVE_NOT_RECRUITING	Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)	Eli Lilly and Company	2024-04-30	PHASE3
NCT07357415	ACTIVE_NOT_RECRUITING	Obesity; Overweight	Eli Lilly and Company	2026-01-24	PHASE3
NCT06859268	ACTIVE_NOT_RECRUITING	Obesity	Eli Lilly and Company	2025-03-05	PHASE3
NCT07035093	ACTIVE_NOT_RECRUITING	Obesity; Overweight; Chronic Low Back Pain (CLBP)	Eli Lilly and Company	2025-05-29	PHASE3
NCT07232719	ACTIVE_NOT_RECRUITING	Obesity; Overweight	Eli Lilly and Company	2025-11-17	PHASE3
NCT07467447	RECRUITING	Obesity	Hudson Biotech	2026-02-15	PHASE2
NCT06982859	ACTIVE_NOT_RECRUITING	Diabetes Mellitus; Insulin Sensitivity	Eli Lilly and Company	2025-06-02	PHASE1
NCT06662383	ACTIVE_NOT_RECRUITING	Obesity	Eli Lilly and Company	2024-11-01	PHASE3
NCT06297603	ACTIVE_NOT_RECRUITING	Type 2 Diabetes	Eli Lilly and Company	2024-03-15	PHASE3
NCT06260722	ACTIVE_NOT_RECRUITING	Diabetes Mellitus, Type 2	Eli Lilly and Company	2024-02-21	PHASE3
NCT05929079	COMPLETED	Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea	Eli Lilly and Company	2023-07-11	PHASE3
NCT06982846	COMPLETED	Type 2 Diabetes Mellitus	Eli Lilly and Company	2025-06-06	PHASE1
NCT05882045	COMPLETED	Obesity; Cardiovascular Diseases	Eli Lilly and Company	2023-05-30	PHASE3
NCT05929066	COMPLETED	Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea	Eli Lilly and Company	2023-07-10	PHASE3
NCT06354660	COMPLETED	Diabetes Type 2	Eli Lilly and Company	2024-04-10	PHASE3
NCT05931367	COMPLETED	Obesity; Overweight; Osteo Arthritis Knee	Eli Lilly and Company	2023-08-01	PHASE3
NCT05936151	COMPLETED	Overweight or Obesity; CKD; Type 2 Diabetes	Eli Lilly and Company	2023-07-20	PHASE2
NCT06808802	COMPLETED	Healthy	Eli Lilly and Company	2025-02-03	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-21)

Check the Retatrutide (LY3437943) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Retatrutide functions as a peptide triple agonist of the glucagon receptor (GCGR), glucagon-like peptide-1 receptor (GLP-1R), and glucose-dependent insulinotropic polypeptide receptor (GIPR), displaying potent activity at human GIPR, GLP-1R, and GCGR with EC50 values of 0.0643 nM, 0.775 nM, and 5.79 nM, respectively. Co-activation of these downstream receptor signaling pathways stimulates nutrient-induced insulin secretion, suppresses appetite, and increases energy expenditure, thereby driving significant body weight reduction and glycemic control in therapeutic contexts such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).